Healthcare provider profile · identity verified

Michael John Couturie, MD

Internal Medicine · NEW HAVEN, CT · NPI 1760684864

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	334	109
Albuterol Sulfate Hfa	Albuterol Sulfate	208	58
Metformin Hcl	Metformin Hcl	186	54
Amlodipine Besylate	Amlodipine Besylate	180	61
Lisinopril	Lisinopril	160	49
Gabapentin	Gabapentin	156	47
Losartan Potassium	Losartan Potassium	142	46
Fluticasone Propionate	Fluticasone Propionate	116	30
Pantoprazole Sodium	Pantoprazole Sodium	105	34
Famotidine	Famotidine	97	27
Rosuvastatin Calcium	Rosuvastatin Calcium	95	33
Montelukast Sodium	Montelukast Sodium	93	26
Ibuprofen	Ibuprofen	84	30
Levothyroxine Sodium	Levothyroxine Sodium	84	27
Ozempic	Semaglutide	83	21
Omeprazole	Omeprazole	82	29
Tamsulosin Hcl	Tamsulosin Hcl	73	26
Hydrochlorothiazide	Hydrochlorothiazide	70	24
Ventolin Hfa	Albuterol Sulfate	63	18
Diclofenac Sodium	Diclofenac Sodium	53	13
Metoprolol Succinate	Metoprolol Succinate	51	22
Trazodone Hcl	Trazodone Hcl	51	19
Hydroxyzine Hcl	Hydroxyzine Hcl	50	19
Oxycodone Hcl	Oxycodone Hcl	49	suppressed
Jardiance	Empagliflozin	47	15
Pravastatin Sodium	Pravastatin Sodium	42	14
Tramadol Hcl	Tramadol Hcl	42	13
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	41	16
Furosemide	Furosemide	40	15
Finasteride	Finasteride	38	suppressed
Naproxen	Naproxen	38	15
Sertraline Hcl	Sertraline Hcl	37	15
Duloxetine Hcl	Duloxetine Hcl	35	13
Meloxicam	Meloxicam	35	suppressed
Allopurinol	Allopurinol	34	12
Donepezil Hcl	Donepezil Hcl	33	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	32	suppressed
Meclizine Hcl	Meclizine Hcl	32	suppressed
Carvedilol	Carvedilol	29	suppressed
Symbicort	Budesonide/Formoterol Fumarate	29	12
Eliquis	Apixaban	28	13
Farxiga	Dapagliflozin Propanediol	26	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	26	suppressed
Alendronate Sodium	Alendronate Sodium	25	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	25	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	25	suppressed
Simvastatin	Simvastatin	23	suppressed
Spironolactone	Spironolactone	23	suppressed
Clopidogrel	Clopidogrel Bisulfate	22	suppressed
Ketoconazole	Ketoconazole	22	suppressed
Nystatin	Nystatin	22	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	21	suppressed
Trulicity	Dulaglutide	21	suppressed
Ondansetron Odt	Ondansetron	20	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	19	suppressed
Pregabalin	Pregabalin	19	11
Zolpidem Tartrate	Zolpidem Tartrate	19	suppressed
Ezetimibe	Ezetimibe	18	suppressed
Tizanidine Hcl	Tizanidine Hcl	18	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	18	suppressed
Butalb-Acetaminoph-Caff-Codein	Butalbit/Acetamin/Caff/Codeine	17	suppressed
Loperamide	Loperamide Hcl	17	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	17	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	16	suppressed
Warfarin Sodium	Warfarin Sodium	16	suppressed
Ammonium Lactate	Ammonium Lactate	15	suppressed
Atenolol	Atenolol	15	suppressed
Glipizide Er	Glipizide	15	suppressed
Buprenorphine-Naloxone	Buprenorphine Hcl/Naloxone Hcl	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Nifedipine Er	Nifedipine	14	suppressed
Citalopram Hbr	Citalopram Hydrobromide	13	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	13	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	13	suppressed
Incruse Ellipta	Umeclidinium Bromide	13	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	13	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	13	suppressed
Chlorthalidone	Chlorthalidone	12	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	12	suppressed
Lyrica	Pregabalin	12	suppressed
Mounjaro	Tirzepatide	12	suppressed
Levetiracetam	Levetiracetam	11	suppressed
Prednisone	Prednisone	11	suppressed
Tradjenta	Linagliptin	11	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error